Tools in the assessment of sarcopenia
C Cooper, R Fielding, M Visser, L J van Loon, Y Rolland, E Orwoll, K Reid, S Boonen, W Dere, S Epstein, B Mitlak, Y Tsouderos, A A Sayer, R Rizzoli, J Y Reginster, J A Kanis, C Cooper, R Fielding, M Visser, L J van Loon, Y Rolland, E Orwoll, K Reid, S Boonen, W Dere, S Epstein, B Mitlak, Y Tsouderos, A A Sayer, R Rizzoli, J Y Reginster, J A Kanis
Abstract
This review provides a framework for the development of an operational definition of sarcopenia and of the potential end points that might be adopted in clinical trials among older adults. While the clinical relevance of sarcopenia is widely recognized, there is currently no universally accepted definition of the disorder. The development of interventions to alter the natural history of sarcopenia also requires consensus on the most appropriate end points for determining outcomes of clinical importance which might be utilized in intervention studies. We review current approaches to the definition of sarcopenia and the methods used for the assessment of various aspects of physical function in older people. The potential end points of muscle mass, muscle strength, muscle power, and muscle fatigue, as well as the relationships between them, are explored with reference to the availability and practicality of the available methods for measuring these end points in clinical trials. Based on current evidence, none of the four potential outcomes in question is sufficiently comprehensive to recommend as a uniform single outcome in randomized clinical trials. We propose that sarcopenia may be optimally defined (for the purposes of clinical trial inclusion criteria as well as epidemiological studies) using a combination of measures of muscle mass and physical performance. The choice of outcome measures for clinical trials in sarcopenia is more difficult; co-primary outcomes, tailored to the specific intervention in question, may be the best way forward in this difficult but clinically important area.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3744387/bin/emss-54295-f0001.jpg)
![Fig.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3744387/bin/emss-54295-f0002.jpg)
Fig.3
1-RM leg extension vs handgrip strength…
Fig.3
1-RM leg extension vs handgrip strength in healthy elderly men and women. Scatter plot…
- Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Cruz-Jentoft AJ, et al. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13. Age Ageing. 2010. PMID: 20392703 Free PMC article.
- Strength measures are better than muscle mass measures in predicting health-related outcomes in older people: time to abandon the term sarcopenia?Menant JC, Weber F, Lo J, Sturnieks DL, Close JC, Sachdev PS, Brodaty H, Lord SR. Menant JC, et al. Osteoporos Int. 2017 Jan;28(1):59-70. doi: 10.1007/s00198-016-3691-7. Epub 2016 Jul 9. Osteoporos Int. 2017. PMID: 27394415
- An elusive consensus definition of sarcopenia impedes research and clinical treatment: A narrative review.Coletta G, Phillips SM. Coletta G, et al. Ageing Res Rev. 2023 Apr;86:101883. doi: 10.1016/j.arr.2023.101883. Epub 2023 Feb 13. Ageing Res Rev. 2023. PMID: 36792012 Review.
- [Definition of sarcopenia and diagnostic evaluation in clinical practice].Trombetti A. Trombetti A. Rev Med Suisse. 2015 Mar 18;11(466):651-6. Rev Med Suisse. 2015. PMID: 25962226 French.
- Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS).Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y, Chen LK, Fielding RA, Martin FC, Michel JP, Sieber C, Stout JR, Studenski SA, Vellas B, Woo J, Zamboni M, Cederholm T. Cruz-Jentoft AJ, et al. Age Ageing. 2014 Nov;43(6):748-59. doi: 10.1093/ageing/afu115. Epub 2014 Sep 21. Age Ageing. 2014. PMID: 25241753 Free PMC article. Review.
- Sarcopenia as a potential risk factor for senile blepharoptosis: Nationwide Surveys (KNHANES 2008-2011).Byeon HJ, Kim YJ, Yoon JS, Ko J. Byeon HJ, et al. Sci Rep. 2023 Mar 29;13(1):5150. doi: 10.1038/s41598-023-31097-7. Sci Rep. 2023. PMID: 36991014 Free PMC article.
- [Impact of osteoporosis on physical performance parameters of middle-aged and elderly individuals-a cross-sectional study].Schröder G, Flachsmeyer D, Bende A, Andresen JR, Andresen R, Schober HC. Schröder G, et al. Orthopadie (Heidelb). 2023 Jan;52(1):54-64. doi: 10.1007/s00132-022-04329-3. Epub 2022 Nov 29. Orthopadie (Heidelb). 2023. PMID: 36445463 Free PMC article. Clinical Trial. German.
- Sarcopenia in head and neck cancer: A scoping review.Jovanovic N, Chinnery T, Mattonen SA, Palma DA, Doyle PC, Theurer JA. Jovanovic N, et al. PLoS One. 2022 Nov 28;17(11):e0278135. doi: 10.1371/journal.pone.0278135. eCollection 2022. PLoS One. 2022. PMID: 36441690 Free PMC article. Review.
- Untargeted muscle tissue metabolites profiling in young, adult, and old rats supplemented with tocotrienol-rich fraction.Saud Gany SL, Tan JK, Chin KY, Hakimi NH, Ab Rani N, Ihsan N, Makpol S. Saud Gany SL, et al. Front Mol Biosci. 2022 Oct 14;9:1008908. doi: 10.3389/fmolb.2022.1008908. eCollection 2022. Front Mol Biosci. 2022. PMID: 36310588 Free PMC article.
- Muscle wasting in cancer: opportunities and challenges for exercise in clinical cancer trials.Fairman CM, Lønbro S, Cardaci TD, VanderVeen BN, Nilsen TS, Murphy AE. Fairman CM, et al. JCSM Rapid Commun. 2022 Jan-Jun;5(1):52-67. doi: 10.1002/rco2.56. Epub 2021 Dec 22. JCSM Rapid Commun. 2022. PMID: 36118249 Free PMC article.
- Research Support, Non-U.S. Gov't
- Review
- Aging
- Body Composition
- Fatigue
- Female
- Humans
- Male
- Muscle Strength
- Muscle, Skeletal / pathology*
- Muscles / pathology
- Randomized Controlled Trials as Topic
- Reproducibility of Results
- Sarcopenia / diagnosis*
- Sarcopenia / therapy*
- Treatment Outcome
- Full Text Sources
- Other Literature Sources
- Medical
![Fig.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3744387/bin/emss-54295-f0003.jpg)
Source: PubMed